MORE safety concerns with dronedarone (Multaq)

October 2011

See the December 2011 completed FDA safety review of Multaq (dronedarone)

There are MORE safety concerns with dronedarone (Multaq).

This time it has to do with the TYPE of atrial fibrillation.

Multaq improves CV outcomes in some patients with PAROXYSMAL or PERSISTENT atrial fib. These resolve spontaneously or with cardioversion.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Anticoagulants controversy over which ORAL anticoagulant to use to prevent strokes in patients with atrial fibrillation
Antidepressants citalopram doses should not exceed 40 mg/day for anyone...or 20 mg/day for most patients over age 60
Antidepressants Reps are filling up sample closets, hoping prescribers will use Deplin to improve the efficacy of antidepressants
Respiratory & Allergy chronic azithromycin to PREVENT recurrent COPD exacerbations
Influenza the first INTRADERMAL flu vaccine
Women's Health tighter and more aggressive control of hypothyroidism before and during pregnancy
Opioids two new opioid formulations, Oxecta and Lazanda
Antipsychotics serious allergic reactions to the antipsychotic, Saphris (asenapine)
Cardiology MORE safety concerns with dronedarone (Multaq)
Geriatrics manage elderly dementia patients who have behavior issues
Interactions Computers often give an "interaction alert" when potassium chloride tabs or caps are combined with an anticholinergic drug
Corticosteroids We're getting questions about whether hyperglycemia can occur with non-oral corticosteroids